Contact
Group lead
Dr Robert Kypta
+44 (0)20 7594 1928
r.kypta@imperial.ac.uk
Related themes
Disease areas
What we do
We study the transduction of extracellular signals that determine cell fate and cell function in prostate cancer, particularly in metastatic and treatment-resistant disease. A major goal is to identify and characterise the cell-surface receptors and effectors of WNT family members and then use the information to develop new therapies.
Why it is important
New treatments for prostate cancer have improved men´s lives but are also leading to the development of more aggressive, treatment-resistant cancer. Our research is aimed at finding new ways to prevent the growth and spread of treatment-resistant cancer.
How it can benefit patients
Our goal is to take the best of the inhibitors and function-blocking antibodies that we are presently studying in the lab to treat patients with prostate and other cancers.
Summary of current research
- Development of antibody nanoparticles for targeted treatment of cancer
- Characterisation of noncanonical Wnt signalling in cancer
Connections
-
Alexandra Porter, Fang Xie, Department of Materials, Imperial College London
-
Maria Vivanco, Center for Cooperative Research in Biosciences, Bilbao, Spain
-
Konstantin Stoletov and John Lewis, University of Alberta, Canada
- Prostate Cancer UK - For information on prostate cancer, helplines manned by trained professionals as well as links to support groups and an online community
When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page.
Our researchers
Dr Robert M Kypta
Dr Robert M Kypta
Associate Professor in Cancer Biology
